[Skip to Content]
[Skip to Content Landing]
Citations 0
October 20, 2004


JAMA. 2004;292(15):1817-1818. doi:10.1001/jama.292.15.1817-b

To the Editor: Dr Yaziji and colleagues1 present a cogent argument for a cost-effective algorithmic approach to HER-2 testing of breast carcinoma based on a carefully conducted and executed study of 2963 samples. We would like to point out several issues not directly addressed in the article or the accompanying editorial.2

First Page Preview View Large
First page PDF preview
First page PDF preview